Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv mecarbil PK/Safety in Healthy Japanese
NCT02601001Phase 1Completed
- Sponsor
- Cytokinetics
- Start
- Nov 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by Cytokinetics. Primary endpoints: Maximum Observed Plasma Concentration at Day 27, Time to Maximum Observed Plasma Concentration at Day 27 and 3 more. Started Nov 2015; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02601001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601001.